Compare Boston Scientific Corporation (BSX) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Consolidated Edison, Inc. — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Consolidated Edison, Inc. trades at $111.89 (market cap $41.26B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Consolidated Edison, Inc. pays a 3.1% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | ED | |
|---|---|---|
Market Cap | $66.37B | $41.26B |
Sector | Health | Utilities |
52-Week High | $108.14 | $115.46 |
52-Week Low | $42.63 | $95.37 |
Enterprise Value | $75.94B | $68.29B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Consolidated Edison (ED) trades at $111.82, up 0.63% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings but maintains stable profitability with a 12.52% net margin. Recent news highlights grid upgrades to meet rising data center demand and the launch of New York's largest electric school bus fleet, supporting long-term growth initiatives.
ED offers a defensive utility profile with a 3.3% dividend yield and 52-year dividend growth streak. However, analyst consensus is cautious with 67% hold ratings and a $103.50 price target below current levels. Key risks include capital expenditure pressures from grid modernization and interest rate sensitivity due to high debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
